Kjær, Mette Skalshøi
Novo Nordisk (Denmark)
7 papers on CoChatORCID 0000-0001-6322-4077
Most cited papers
- Verified
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
Sanyal, A. J., Newsome, P. N., Kliers, I., Østergaard, L. H., Long, M. T., Kjær, M. S., Cali, A. M. G., Bugianesi, E., Rinella, M. E., Roden, M., et al. (2025) · New England Journal of Medicine
Liver Disease Diagnosis and TreatmentDiabetes Treatment and Management
Cited by 1,115
- Verified
Semaglutide 2· 4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial
Loomba, R., Abdelmalek, M. F., Armstrong, M. J., Jara, M., Kjær, M. S., Krarup, N., Lawitz, E., Ratziu, V., Sanyal, A. J., Schattenberg, J. M., et al. (2023) · The Lancet Gastroenterology & Hepatology
Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation
Cited by 533
- Verified
Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: a systematic review and meta-analysis
Selvaraj, E. A., Mózes, F. E., Jayaswal, A. N. A., Zafarmand, M. H., Vali, Y., Lee, J. A., Levick, C. K., Young, L. A. J., Palaniyappan, N., Liu, C.-H., et al. (2021) · Journal of Hepatology
Liver Disease Diagnosis and TreatmentUltrasound Imaging and Elastography
Cited by 376
- Verified
An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD)
Vacca, M., Kamzolas, I., Harder, L. M., Oakley, F., Trautwein, C., Hatting, M., Ross, T., Bernardo, B., Oldenburger, A., Hjuler, S. T., et al. (2024) · Nature Metabolism
Liver Disease Diagnosis and TreatmentDiet, Metabolism, and Disease
Cited by 262
- Verified
Alcohol drinking pattern and risk of alcoholic liver cirrhosis: A prospective cohort study
Askgaard, G., Grønbæk, M., Kjær, M. S., Tjønneland, A., & Tolstrup, J. S. (2015) · Journal of Hepatology
Alcohol Consumption and Health EffectsSubstance Abuse Treatment and Outcomes
Cited by 256
- Verified
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial
Alkhouri, N., Herring, R., Kabler, H., Kayali, Z., Hassanein, T., Kohli, A., Huss, R. S., Zhu, Y., Billin, A. N., Damgaard, L. H., et al. (2022) · Journal of Hepatology
Liver Disease Diagnosis and TreatmentHepatitis C virus research
Cited by 230
- Verified
Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis
Mózes, F. E., Lee, J. A., Vali, Y., Alzoubi, O., Staufer, K., Trauner, M., Paternostro, R., Stauber, R. E., Holleboom, A. G., van Dijk, A.-M., et al. (2023) · The Lancet Gastroenterology & Hepatology
Liver Disease Diagnosis and TreatmentLiver Disease and Transplantation
Cited by 214
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free